BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — Biotech Capital — Investor Presentation (February 2017)
13 slides from BTC Health Ltd Registered's investor presentation, Feb 10, 2017
Slide 1: Investor Presentation
For personal use only Investor Presentation 10 February 2017
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations and assumptions reflected in the forward looking statements are reasonable at this time, Biotech Capital can give no
Slide 3: Company Snapshot
Company Snapshot For personal use only • Stock code ASX: BTC – market cap approximately $13m • Biotech Capital Limited is registered as a Pooled Development Fund (PDF) under the Pooled Development Fund Act, 1992 • Experienced Board with strong industry profile and PDF expertise • Headquartered in Me
Slide 4: Pooled Development Fund Summary
Pooled Development Fund Summary For personal use only Shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived from their shareholding. Gains realised on the disposal of shares will not be included in an investor’s assessable income in Australia. An
Slide 5: Strategy
Strategy For personal use only • Continue to expand the group’s development and commercialisation capabilities • Committed to building the core business, but responsive to bolt-on opportunities • Pursuing higher value-add investments, through acquiring rights to novel drugs and medical devices • Bui
Slide 6: Share price – years
Share price – 5 years For personal use only 0.2 0.18 0.16 0.14 0.12 0.1 BIOINTELECT 0.08 ACQUISITION 0.06 WALKER INVESTMENT 0.04 0.02 BOARD CHANGES 0
Slide 7: Shareholding and financial position
Shareholding and financial position For personal use only Cash reserves at 31 January 2017: $786k NTA at 31 January 2017: $2.31m Shares outstanding: 108.6m Options outstanding: 2m (exercise price 15.9c) Market capitalisation: $13m Closing price 10 February 2017: 12 cents 52 week range: 9.0 cents – 1
Slide 8: Board
Board For personal use only Richard Treagus – Executive Chairman Peter Jones – Non Executive Director Bruce Hancox – Non Executive Director Jon Pilcher – Non Executive Director and Head of Audit Committee Jennifer Herz – Non Executive Director and Managing Director of Biointelect Stuart Jones – Comp
Slide 9: Company Structure
Company Structure For personal use only “Bringing Science to Market” “Your finance and company “Your commercialisation administration experts in partner in Asia-Pacific” Australia”
Slide 10: Biointelect acquired - April '16
For personal use only Biointelect acquired - April ’16: Growth plans and outlook: • Biointelect fully integrated into the Biotech • Expanding core services in Regulatory, Capital Group Quality and Clinical development • Revenue has been steadily increasing • Establish Biointelect Melbourne office •
Slide 11: Bio101 acquired - June '16
For personal use only Bio101 acquired - June ’16: Growth plans and outlook: • Positioned as the preferred provider of • Bio101 fully integrated into the Biotech financial, tax, R&D rebate and company Capital Group administration services in the life science • Business systems and processes now fully
Slide 12: BioImpact established – Nov '16
For personal use only BioImpact established – Nov ’16: • Established to acquire and/or in-license intellectual property rights • Focused on speciality pharmaceuticals and medical devices • Experienced in-licensing executive will commence later this month • Partnering with international companies tha
Slide 13: Strategic Priorities
Strategic Priorities For personal use only Continue to support and drive core business growth - Expand service offering of Biointelect in the key areas of Regulatory, Quality and Clinical development - Establish a Melbourne presence for Biointelect services - Increase the profile of the BTC group se
Biotech Capital — Investor Presentation (February 2017) on 6ix